03:44 AM EDT, 06/16/2025 (MT Newswires) -- Incyte ( INCY ) said Sunday that data from two studies of its monoclonal antibody treatment INCA033989 showed "rapid and durable normalization of platelet counts" in patients with mutant calreticulin-expressing myeloproliferative neoplasms.

Myeloproliferative neoplasms are a group of blood cancers in which the bone marrow functions abnormally.

The data, gleaned from the dose-escalation portion of the ongoing studies, showed that 86% of patients treated with the doses of 400 milligrams or above achieved a complete or partial hematologic response, while 89% of those responsive to the drug showed a reduction in peripheral blood mutCALR variant allele frequency, the company said.

The company also said the data from the studies show the drug candidate could modify the disease by "directly inhibiting and eliminating" cancerous cells without damaging healthy cells and restoring normal cell production.

The company said it plans to conduct discussions with regulatory authorities with the aim of initiating a phase 3 study by early 2026.